Oncology Clinical Pathways Spotlight
This week in health care trends, our oncology clinical pathways spotlight includes a video about bundled payments, a report on costly new leukemia drugs, and study findings that may boost lung cancer trial enrollment.
The articles below are from our dedicated Oncology Clinical Pathways e-magazine. We’re constantly adding valuable content to this updateable magazine, so make sure to check our e-magazine frequently for new intelligence. You can follow us on Flipboard or Twitter, or just watch for the links to this and our other magazines in our regular weekly BioBlog emails. (Don’t get our emails yet? Subscribe here!)
As organizations around the country continue to experiment with alternate reimbursement models, many are trying bundled payments. But what are bundled payments? This short, engaging video provides a thorough definition and context for the increasing use of bundled payments in the U.S.
In a recent study, researchers at Mayo Clinic examined two new drugs used for treatment of chronic lymphocytic leukemia (CLL). About the drugs, the report concluded, “Although ibrutinib and idelalisib are profound treatment advances, they will dramatically increase individual out-of-pocket and societal costs of caring for patients with CLL. These cost considerations may undermine the potential promise of these agents by limiting access and reducing adherence.”
A recent study of lung cancer trial patients argues that “Prior cancer history should not exclude patients with advanced lung cancer from participating in clinical trials because it does not impact outcomes.” The study, published in the Journal of the National Cancer Institute, followed over 100,000 patients diagnosed with lung cancer and found that “patients with prior cancer had 10% overall survival and 20% better lung cancer–specific survival than those with no previous cancer diagnosis.”